Carvedilol: a review of its use in the management of heart failure
| Autor: | Ramandeep Sharma, Hiren Prajapati, Dixit K. Patel |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Sympathetic nervous system business.industry Management of heart failure 030204 cardiovascular system & hematology medicine.disease Dialysis patients 03 medical and health sciences Cardiovascular reflexes 0302 clinical medicine Pharmacotherapy medicine.anatomical_structure Tolerability Heart failure Internal medicine medicine Cardiology Pharmacology (medical) 030212 general & internal medicine business Carvedilol medicine.drug |
| Zdroj: | Drugs & Therapy Perspectives. 33:147-152 |
| ISSN: | 1179-1977 1172-0360 |
| DOI: | 10.1007/s40267-016-0370-x |
| Popis: | Heart failure (HF) is a major public health issue with an increasing burden worldwide. The abnormalities in cardiovascular reflexes are responsible for the sympathetic hyperactivity in HF. Interrupting the activated sympathetic nervous system with β-blockers is a promising approach to alter the natural course of HF. Carvedilol is a third-generation β-blocker that offers not only non-selective β- and α1-adrenoreceptor antagonism properties, but also multiple cardioprotective effects that are beneficial in HF management. Carvedilol is a well studied β-blocker with numerous reports of efficacy across all stages of HF, as well as HF in dialysis patients. The better therapeutic efficacy and tolerability profiles of carvedilol compared with β1-selective β-blockers should make carvedilol an attractive option in the management of HF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink